Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
Zhenhua FanTao OuyangJinfeng LiTianfeng WangZhaoqing FanTie FanBenyao LinYe XuYuntao XiePublished in: Breast cancer research and treatment (2018)
Among Chinese breast cancer patients, the CHEK2 germline mutation rate is approximately 0.34% and two specific mutations (Y139X and R137X) are recurrent. Patients with CHEK2 mutations are significantly more likely to have family histories of cancer, and to develop lymph node-positive and/or PR-positive breast cancers.